tients using an Excel spreadsheet was successful, and 100%
of HNC patients had received follow-up appointments. However, the manual process of tracking HNC patients on an
Excel spreadsheet was time consuming with limited func-tionality.
Phase II – A robust automated electronic identification
system was implemented for tracking HNC patients which
included additional features that far exceeded the capabilities
of manual tracking.
Data Analysis: During the first 8 months of its operation
(February 2014 – September 2014) 25 newly diagnosed HNC
patients were identified electronically; patients that manual
tracking might have missed.
Results: FY15 and FY16 targeted goal was achieved. 100%
of HNC patient appointments were recaptured for cancer surveillance that otherwise might have been lost to follow-up
using the automated electronic tracking system.
Implications: The automated HNC Dashboard has proved
to be a vital tool providing improved access to care. It can be
used and customized for tracking other cancer types.
34. Targeting Intracellular Pathways in
Kratzke MG, Kren BT, Klein MA
Purpose: The purpose of this study is to determine the efficacy of inhibition of mitochondrial antioxidant defense
against mesothelioma and whether the cyclin-dependent kinase 4 (CDK4) inhibitor palbociclib sensitizes mesothelioma
cells to inhibition of mitochondrial antioxidant defense.
Background: Mesothelioma is a highly fatal cancer with
limited therapeutic options. Low expression of the endogenous CDK4 inhibitor p16INK4A has been demonstrated
in up to 90% of mesothelioma tumors. CDK4 has also been
demonstrated to activate manganese superoxide dismutase,
which can decrease superoxide levels in cells and may make
them less susceptible to induction of apoptosis. Downregu-lation of the key mitochondrial antioxidant protein, thiore-doxin 2 (Trx2) has been demonstrated to increase reactive
oxygen species production in mesothelioma cells resulting
in reduced mesothelioma tumor growth. Gentian violet has
been demonstrated to result in decreased expression of Trx2,
a key mitochondrial antioxidant protein. The goal of this
project is to determine whether concomitant targeting of the
cell cycle and mitochondrial antioxidant pathways lead to improved efficacy against mesothelioma.
Methods: Mesothelioma cells were treated with compound
or control and proliferation was evaluated using Cell Counting Kit 8 (Dojindo). For immunoblotting experiments, detection was performed using enhanced chemiluminescence.
Apoptosis was detected via Cell Death Detection ELISAPLUS
(Sigma-Aldrich). All experiments were done in duplicate or
Data Analysis: IC50 curves were fitted via Origin software.
Results: Previously, we have demonstrated that palbociclib
inhibits mesothelioma cell proliferation, inhibits retinoblas-
toma protein (Rb) phosphorylation, and results in cell cycle
arrest. Mesothelioma cells in culture were treated with palbo-
ciclib and gentian violet alone and in combination. After 72h
incubation with gentian violet, decreased cell proliferation
was observed for 3 separate cell lines (IC50 = 365 nM, 870
nM, and 920 nM, respectively). Incubation with gentian vio-
let for 24h resulted in decreased expression of Trx2 in all cell
lines and also induced apoptosis in all cell lines. Gentian vio-
let sensitized mesothelioma cells to palbociclib in a cell prolif-
Implications: Gentian violet resulted in a significant decrease in mesothelioma cell proliferation. Palbociclib also
sensitizes mesothelioma cells to gentian violet. Further investigation of this combination approach may demonstrate these
combinations are useful for mesothelioma treatment.
35. AVAHO Health Services Research
Subcommittee: A Productive
Henry E, Silva A, Zullig LL, Crawford R, Faricy-Anderson K,
Klein MA, Houranieh J, Aggarwal A, Mobarek D, Graf S,
Lee SP, Gill T, Lynch J
Purpose: The purpose is to describe the development and
design of the AVAHO Health Services Research (HSR) subcommittee and its productivity in developing inter-institutional partnerships. Our overarching objective is to increase
awareness of the HSR subcommittee among AVAHO members.
Background: The AVAHO HSR subcommittee was established in 2013 to develop inter-institutional partnerships
among AVAHO members who are interested in addressing
oncology HSR questions relevant to the VA and its patients.
The 10 founding members of the subcommittee represented 8 VA institutions.
Methods: The HSR subcommittee meets via teleconference
every second Friday of the month. Joint and individual
projects are developed. Meeting agenda items typically include: project idea development, project progress updates,
AVAHO updates, clinical trial opportunities, and funding
opportunities. Subcommittee progress is presented at AVAHO’s annual meetings.
Data Analysis: We will use descriptive statistics and
Results: The HSR subcommittee has grown to include 21
members from 16 VA institutions. Membership includes
practitioners from medical oncology, radiation oncology, internal medicine, oncology pharmacy, and oncology nursing, as well as health services researchers. Members have
wide-ranging research expertise. As an inaugural project,
we developed a protocol to examine the characteristics and
treatment patterns of patients with castration resistant prostate cancer in the VA health care system nationwide. Pilot
funding from the Hines VA was obtained to carry out the
project using VA administrative and claims data. The protocol and preliminary study results were presented at the
2014 and 2015 AVAHO annual meetings, respectively. Updated results have been submitted for presentation at the